Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): A trial of the Eastern Cooperative Oncology Group

William R. Friedenberg, Martin S. Tallman, Isadore Brodsky, Elisabeth Paietta, Jacob M. Rowe, Sandra J. Lee, Kendrith M. Rowland, George W. Schnetzer, John C. Reed

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Background & method: The role of multidrug resistance (MDR) was investigated in patients with relapsed chronic lymphocytic leukemia (CLL). PSC-833 was added to modified VAD (a 4-day infusion of vincristine, doxorubicin, with oral dexamethasone, every 3 weeks), in an attempt to improve the response rate (21%) in a prior study. Laboratory tests to determine MDR and apoptosis proteins were correlated with response. Results: Two of the seven MDR-positive cases and one of the four MDR-negative patients achieved a partial response (no significant difference). No significant correlation with response was found in any of the laboratory tests for apoptosis. Conclusion: VAD plus PSC-833 had the same (21%) partial response rate as a prior ECOG study without PSC-833. No correlation of response with MDR or apoptosis testing was found. Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL.

Original languageEnglish (US)
Pages (from-to)813-819
Number of pages7
JournalLeukemia Research
Volume28
Issue number8
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

Keywords

  • Chronic lymphocytic leukemia
  • Multidrug resistance
  • PSC-833
  • p-Glycoprotein

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): A trial of the Eastern Cooperative Oncology Group'. Together they form a unique fingerprint.

  • Cite this